fda warning letters compounded semaglutide tirzepatide 2024 2025 August 11, 2025: The voices concern about sites that supply compounding ingredients – Partnership for Safe Medicines FDA warns companies over unapproved

Preclinical toxicity evaluations indicate that intravenous administration of AsVI at 1.0 mg/kg in rats induces maternal toxicity, while doses exceeding 0.5 mg/kg exhibit fetotoxic effects without teratogenicity (Jiangbo et al., 2009)

The injection site is located in the middle of the deltoid , which is roughly 2-3 finger widths below the acromion

Recognising Plateau Patterns Recognising plateau patterns helps patients identify when theyre experiencing a temporary stall versus when they may need to adjust their approach

It increases hepatic glucose output in the short term, which sounds counterintuitive for a metabolic drug, but the body compensates through increased energy expenditure